Shanghai Yanjian

Yanjian Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative peptide-based therapeutics for metabolic and endocrine diseases. The company's primary focus is on multi-target agonists, including dual GLP-1/GIP and triple GLP-1/GIP/Glucagon receptor agonists, aimed at treating obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Leveraging its proprietary peptide engineering platform, Yanjian Biotech aims to optimize the pharmacological profiles of its candidates to improve efficacy and safety over existing treatments. The company has advanced several programs into clinical trials, positioning itself as a competitive player in the rapidly evolving metabolic drug market.